Candel Therapeutics advances Phase 2b trial for innovative prostate cancer treatment

5 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Candel Therapeutics Chief Medical Officer Garrett Nichols spoke with Steve Darling from Proactive to provide updates on the company’s Phase 2b trial of their innovative treatment, designed for patients with localized early prostate cancer.

The trial involves 188 men with low to intermediate-risk prostate cancer—individuals who often choose active surveillance to avoid the side effects of invasive treatments. However, the psychological burden of potential disease progression frequently pushes patients toward radical options, such as prostate removal surgery.

The study aims to compare outcomes between patients receiving two doses of the treatment, administered alongside a prodrug, and those continuing with active surveillance alone. The primary goal is to reduce biopsy-confirmed progression rates in this population.

If proven effective, this therapy could become the first non-invasive option for managing prostate cancer in these patients, addressing a significant unmet need. “Our goal is to demonstrate a meaningful reduction in the risk of progression,” Dr. Nichols stated, highlighting the potential for the treatment to reshape care standards pending further clinical validation in Phase 3 trials.

#proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #prostatecancer
#ProstateCancer #CAN2409 #CancerResearch #ClinicalTrials #ProstateHealth #ActiveSurveillance #MedicalInnovation #Biotech #Oncology#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
Category
Oncology
Be the first to comment

Up Next